Medicare Enrolled
Dr. Navneet Mittal, MD
Hematology & Oncology · Live Oak, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mittal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mittal?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mittal
Dr. Navneet Mittal is a hematology & oncology specialist in Live Oak, TX, with 18 years of NPI registration. Based on federal Medicare data, Dr. Mittal performed 45,106 Medicare services across 1,812 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mittal received a total of $8,417 from 58 pharmaceutical and/or device companies across 368 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mittal is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 21% volume in TX
$8,417 industry payments
Medicare Practice Summary
Medicare Utilization ↗45,106
Medicare services
Top 21% in TX for hematology & oncology
1,812
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,506 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Monoferric) | 13,000 | $17 | $43 |
| Denosumab injection (Prolia/Xgeva) | 11,520 | $18 | $47 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
5,672 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
3,820 | $6 | $16 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,120 | $6 | $16 |
| Anti-nausea injection (ondansetron/Zofran) | 3,072 | $0 | $2 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,289 | $63 | $176 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
609 | $11 | $27 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
527 | $22 | $56 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
420 | $97 | $249 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
405 | $100 | $252 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
226 | $45 | $123 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
202 | $1 | $2 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
178 | $50 | $124 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
135 | $22 | $54 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
128 | $1 | $3 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
118 | $15 | $38 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
97 | $134 | $349 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
87 | $12 | $29 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
85 | $15 | $40 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
71 | $115 | $324 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
71 | $2 | $5 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
57 | $18 | $49 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
56 | $25 | $63 |
| New patient office visit, complex (60-74 min) | 44 | $167 | $428 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
36 | $62 | $155 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
35 | $41 | $176 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
26 | $76 | $218 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.5% high complexity
62.9% medium
4.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,417
Total received (2018-2024)
Avg $1,202/year across 7 years
Top 34% in TX for hematology & oncology
58
Companies
368
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,326 (98.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$91 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,540
2023
$2,538
2022
$929
2021
$339
2020
$363
2019
$965
2018
$744
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
US Oncology Corporate, Inc.
$1,113
Novartis Pharmaceuticals Corporation
$1,096
AstraZeneca Pharmaceuticals LP
$561
E.R. Squibb & Sons, L.L.C.
$555
Genentech USA, Inc.
$515
Daiichi Sankyo Inc.
$470
Janssen Biotech, Inc.
$446
PFIZER INC.
$380
Seagen Inc.
$341
Lilly USA, LLC
$264
Amgen Inc.
$175
GlaxoSmithKline, LLC.
$174
Bayer Healthcare Pharmaceuticals Inc.
$136
GENZYME CORPORATION
$134
Celgene Corporation
$132
Bayer HealthCare Pharmaceuticals Inc.
$127
Novo Nordisk Inc
$115
Amneal Pharmaceuticals LLC
$102
Astellas Pharma US Inc
$100
Verastem, Inc.
$93
Intuitive Surgical, Inc.
$92
Takeda Pharmaceuticals U.S.A., Inc.
$83
ARRAY BIOPHARMA INC
$70
CTI BioPharma Corp.
$67
ERBE USA Inc
$66
Regeneron Healthcare Solutions, Inc.
$65
Janssen Pharmaceuticals, Inc
$64
Dendreon Pharmaceuticals LLC
$59
Exelixis Inc.
$58
Puma Biotechnology, Inc.
$56
Merck Sharp & Dohme Corporation
$56
Karyopharm Therapeutics Inc.
$48
Merck Sharp & Dohme LLC
$47
Sumitomo Pharma America, Inc.
$46
Pharmacyclics LLC, An AbbVie Company
$44
TAIHO ONCOLOGY, INC.
$39
Kyowa Kirin, Inc.
$33
AMAG Pharmaceuticals, Inc.
$33
Gilead Sciences, Inc.
$29
Spectrum Pharmaceuticals Inc.
$26
Pharmacosmos Therapeutics Inc.
$25
Cumberland Pharmaceuticals, Inc.
$23
PharmaEssentia USA Corporation
$23
ADC Therapeutics America, Inc.
$22
Taiho Oncology, Inc.
$21
JAZZ PHARMACEUTICALS INC.
$20
AVEO Pharmaceuticals, Inc.
$19
NOVARTIS PHARMACEUTICALS CORPORATION
$18
Eisai Inc.
$18
EUSA Pharma (US) LLC
$17
Teva Pharmaceuticals USA, Inc.
$16
Agios Pharmaceuticals, Inc.
$15
ABBVIE INC.
$14
Seattle Genetics, Inc.
$13
Advanced Accelerator Applications
$12
BeiGene USA, Inc.
$11
Foundation Medicine, Inc.
$11
Clovis Oncology, Inc.
$10
Top 3 companies account for 32.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · AVASTIN · Alecensa · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · Da Vinci Surgical System · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · ERLEADA · Enhertu · Erbe CRYO2 · Erleada · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · Halaven · IBRANCE · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lunsumio · Lutathera · MEKINIST · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · ORGOVYX · Ozempic · PADCEV · PIQRAY · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SHINGRIX · SPRYCEL · Stivarga · Sylvant · TASIGNA · TECENTRIQ · TECVAYLI · TUKYSA · Tecentriq · VERZENIO · VOTRIENT · Vectibix · Venclexta · Vonjo · Vyloy · XARELTO · XPOVIO · XTANDI · Xtandi · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $19 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
59
Per 100K population
2.9
County median income
$70,571
Nearest hospital
LAUREL RIDGE TREATMENT CENTER
5.9 mi
5.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Mittal is a mixed practice specialist, with above-average Medicare volume (top 21% in TX), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Mittal experienced with iron infusion (monoferric)?
Based on Medicare claims data, Dr. Mittal performed 13,000 iron infusion (monoferric) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mittal receive payments from pharmaceutical companies?
Yes. Dr. Mittal received a total of $8,417 from 58 companies across 368 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mittal's costs compare to other hematology & oncology specialists in Live Oak?
Dr. Mittal's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mittal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Live Oak
Browse hematology & oncology specialists in Live Oak ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
US Oncology Corporate, Inc. Payments to Doctors
See all physicians who received payments from US Oncology Corporate, Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology